eznews.inA promising new weight loss drug, eloralintide, has demonstrated significant efficacy in Phase 2 clinical trials, achieving an average weight loss of 9-20% among participants over 48 weeks. Unlike established GLP-1 medications such as Ozempic and Wegovy, which are not universally effective and may leave up to 17% of users as "non-responders," eloralintide targets the hormone amylin, regulating appetite and metabolism. The trial included 263 adults with obesity or overweight, revealing that those treated with eloralintide experienced substantial health improvements, including reductions in hypertension and sleep apnea symptoms. Experts emphasize the importance of long-term safety and sustainability of results, with plans for Phase 3 trials to further assess its effectiveness across a diverse population. The development of eloralintide could enhance treatment options for obesity, providing a vital alternative to existing therapies and potentially expanding the therapeutic toolbox for personalized weight management. 
Published: Nov 20 2025, 11 pmeznews.inResearchers are exploring natural alternatives to GLP-1 medications like Ozempic, which have revolutionized weight management and type 2 diabetes treatment. A review from Heliopolis University in Cairo highlights the potential of dietary compounds such as cinnamon, ginger, and green tea to influence the gut hormone glucagon-like peptide-1 (GLP-1), which is targeted by these medications. The search for natural substitutes is driven by the high cost and accessibility issues associated with GLP-1 injections, as well as concerns over their gastrointestinal side effects. While some natural ingredients may enhance metabolism, experts caution that their effects are mild and should not replace traditional medications. Dr. Mir Ali emphasizes the importance of a balanced diet and exercise in achieving sustainable weight loss, noting that while natural compounds can support weight management, they are not a substitute for comprehensive lifestyle changes or medical treatments.
Published: Nov 20 2025, 2 pmeznews.inRecent research indicates that the DASH (Dietary Approaches to Stop Hypertension) diet may significantly reduce the risk of complications associated with type 2 diabetes, a condition affecting over 500 million people globally. The diet, originally designed to lower blood pressure, combines high potassium, magnesium, calcium, and fiber with low sodium and saturated fats, which can enhance insulin sensitivity and improve cardiovascular health. A review published in *Frontiers in Nutrition* highlights the diet's effectiveness in regulating blood glucose levels and reducing inflammation, thereby protecting vital organs like the heart and kidneys. While the DASH diet may not dramatically lower hemoglobin A1c levels, it offers broader health benefits, including improved kidney function and reduced cardiovascular risks. Experts advise that the diet is suitable for most individuals with type 2 diabetes, although those with kidney issues or on glucose-lowering medications should consult their doctors before making dietary changes.
Published: Nov 20 2025, 3 ameznews.inA recent study has identified a potential link between the Epstein-Barr virus (EBV) and lupus, an autoimmune disease affecting over 5 million people globally. Researchers at Stanford University have found that nearly all lupus patients have evidence of past EBV infections and generate heightened immune responses to the virus. The study revealed that individuals with lupus have 25 times more EBV-infected B cells in their blood compared to healthy individuals. These cells, which can become pro-inflammatory, are believed to drive the autoimmune response associated with lupus. Senior author Dr. William Robinson emphasized that targeting these EBV-infected B cells could lead to transformative treatments or even a cure for lupus. The findings also raise questions about the role of EBV in other autoimmune diseases, suggesting that effective EBV suppression might mitigate autoimmune responses in patients. Further research is needed to validate these mechanisms and explore their implications for broader autoimmune conditions.
Published: Nov 19 2025, 12 pmeznews.inA recent review published in the *Cochrane Library* has found that low-dose colchicine, a medication traditionally used for gout, may effectively reduce the risk of heart attacks and strokes in patients with existing cardiovascular disease. The comprehensive analysis of twelve studies, involving nearly 23,000 participants, indicated that colchicine could lead to nine fewer heart attacks and eight fewer strokes per 1,000 individuals treated. However, it appears not to affect overall mortality rates or coronary revascularization outcomes. While the drug may have gastrointestinal side effects, these are generally mild. Experts caution that colchicine should be reserved for high-risk patients, given its narrow therapeutic index and potential interactions with other medications. The findings suggest colchicine could be a valuable addition to secondary prevention strategies in cardiovascular care, but its use should be tailored to individual patient needs, particularly in those with chronic, stable coronary artery disease.
Published: Nov 19 2025, 12 ameznews.inResearchers have identified early brain changes that may facilitate the diagnosis of Alzheimer’s disease (AD) before significant cognitive decline occurs. Traditionally, individuals are diagnosed only after irreversible brain damage has manifested, often through cognitive tests and imaging for amyloid beta protein aggregates. A recent study, published in *Alzheimer’s and Dementia*, utilized brain imaging data from 403 participants to reveal specific patterns of metabolic activity and cerebral blood flow alterations in various brain regions during the progression of AD. The study suggests that these changes could serve as biomarkers for early diagnosis, potentially allowing for individualized treatment strategies. However, experts caution that further research is necessary to validate these findings across diverse datasets and to assess their predictive accuracy. Jurgen Claassen, an independent expert, emphasized the need for cautious interpretation of these results, highlighting the importance of replicating the study in different cohorts.
Published: Nov 18 2025, 1 ameznews.inRecent research has highlighted the potential health benefits of vitamin D, particularly in relation to longevity and disease prevention. A comprehensive review of 50 studies involving over one million participants indicated that higher vitamin D levels may reduce the risk of colorectal cancer and improve survival rates for those affected. Additionally, studies suggest that vitamin D3 supplementation could significantly lower the risk of repeat heart attacks, with findings showing a reduction from 7.9% in the control group to 3.8% in the treatment group. Furthermore, vitamin D may play a role in slowing biological aging by preserving telomere length in white blood cells, potentially equating to a three-year reduction in biological age. However, experts emphasize the need for further research, particularly large-scale clinical trials, to better understand vitamin D's effects and establish personalized supplementation guidelines, as factors like genetics and lifestyle can influence individual responses.
Published: Nov 16 2025, 3 pmeznews.inRecent research has shed light on the complex relationship between caffeine consumption and depression treatments, particularly for those with treatment-resistant depression. While standard antidepressants often fail for many, ketamine and electroconvulsive therapy (ECT) can be effective by inducing surges of adenosine, a crucial signaling molecule in the brain. However, caffeine, a common adenosine receptor antagonist, may hinder the effectiveness of these treatments, leading to what researchers call the "coffee paradox." Despite evidence that regular coffee consumption can reduce depression risk by up to 25%, it is suggested that caffeine intake prior to ketamine or ECT could diminish their benefits. Experts recommend that individuals scheduled for these treatments avoid caffeine for at least 24 hours beforehand, emphasizing the need for further clinical studies to explore caffeine's impact on treatment efficacy and to develop therapies that work in harmony with adenosine signaling.
Published: Nov 15 2025, 5 pmeznews.inRecent research has revealed that GLP-1 receptor agonists, commonly used for managing type 2 diabetes and weight loss, may significantly reduce mortality risk in patients with colon cancer. A study led by Dr. Raphael Cuomo at UC San Diego analyzed data from over 6,800 adults diagnosed with colon cancer, finding that those using GLP-1 medications had a 15.5% five-year mortality rate compared to 37.1% for non-users. This suggests a potential survival advantage linked to the drugs' ability to improve insulin sensitivity, reduce inflammation, and potentially influence tumor biology. Experts, including oncologist Dr. Anton Bilchik, emphasized that the anticancer effects could stem from weight loss or direct impacts on the immune environment and inflammation. As research progresses, further studies are planned to explore these mechanisms and the role of GLP-1 drugs in cancer treatment, indicating their potential for broader therapeutic applications.
Published: Nov 15 2025, 4 ameznews.inResearchers at the Mayo Clinic have developed a groundbreaking model to predict the risk of Alzheimer’s-related cognitive decline, utilizing amyloid PET scans and genetic data. This tool estimates both lifetime and 10-year risks for developing mild cognitive impairment (MCI) and dementia, even before symptoms manifest. The study tracked over 5,100 adults aged 50 and older over two decades, revealing a strong correlation between amyloid buildup in the brain and increased risk, particularly in those carrying the APOE4 gene. For instance, a 75-year-old man with APOE4 and high amyloid levels faces a 76% lifetime risk of MCI. While the model shows promise for guiding early interventions, lead researcher Dr. Clifford Jack emphasized it is currently for research purposes only, pending regulatory approval for related treatments. Experts hailed the study as a significant advancement in predictive neuroscience, though they noted the challenges of accessibility and cost associated with amyloid PET scans.
Published: Nov 14 2025, 11 pmFor the fastest, latest, not so wokest news, 'experts say' you need to visit Eznews
India
World
Economy
Science
Health
Showbiz
Contact